Mild skin photosensitivity in cancer patients following injection of Photochlor (2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a; HPPH) for photodynamic therapy
- 337 Downloads
Purpose: To measure skin photosensitivity in cancer patients infused with the new second-generation photodynamic sensitizer Photochlor (2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a). A major disadvantage of using the clinically approved photosensitizer Photofrin is potentially prolonged and sometimes severe cutaneous phototoxicity. Patients and methods: Forty-eight patients enrolled in Phases 1 and 2 clinical trials underwent two or more exposures to four graded doses (44.4, 66.6, 88.8 or 133.2 J/cm2) of artificial solar-spectrum light (SSL) before and after administration of Photochlor at a dose of 2.5, 3, 4, 5 or 6 mg/m2 . Results: The most severe skin response, experienced by only six of the subjects, was limited to erythema without edema and could only be elicited by exposure to the highest light dose. Conversely, eight subjects had no discernible reaction to SSL at any light dose. For nearly all the patients, the peak skin response was obtained when the interval between sensitizer injection and exposure to SSL was 1 day and, generally, their sensitivity to SSL decreased with increasing sensitizer-light interval. For example, a 2-day sensitizer-SSL interval resulted in less severe reactions than those obtained with the 1-day interval in 79% of the subjects, while 90% of the subjects exposed to SSL 3 days after Photochlor infusion had responses that were less severe than those obtained with either the 1- or 2-day sensitizer-SSL interval. Conclusions: Photochlor, at clinically effective antitumor doses, causes only mild skin photosensitivity that declines rapidly over a few days.
KeywordsHPPH Photochemotherapy Photodynamic therapy Photofrin Phototoxicity Solar simulator
This study was supported in part by NIH Grant PO155791 and the Oncologic Foundation of Buffalo, and utilized core facilities supported in part by Roswell Park Cancer Institute’s National Cancer Institute-funded Cancer Center Support Grant CA16056. The authors wish to thank Leroy Wood, Kenneth R. Keymel and Adam Sumlin for performing the clinical phototests, and Dr. Ian MacDonald for helpful suggestions in preparing this manuscript.
- 5.Dougherty TJ, Levy JG (2003) Photodynamic therapy (PDT) and clinical applications Biomedical photonics handbook. CRC, Boca RatonGoogle Scholar
- 7.Eljamel MS (2003) New light on the brain: the role of photosensitizing agents and laser light in the management of invasive intracranial tumors. Tech Cancer Res Treat 2:303–309Google Scholar
- 12.Moghissi K, Dixon K (2003) Photodynamic therapy (PDT) in esophageal cancer: a surgical view of its indications based on 14 years experience. Tech Cancer Res Treat 2:319–326Google Scholar
- 14.Pandey RK (2004) Synthetic strategies in designing porphyrin-based photosensitizers for photodynamic therapy. CRC handbook of organic photochemistry and photobiology. CRC, Boca RatonGoogle Scholar